Beyond Detection: What Comes Next for Neurodegenerative Biomarkers
Advances in biomarkers are transforming neurodegenerative disease research and trials.
For years, one of the central challenges in neurodegenerative disease research was finding ways to identify disease earlier.
Work on Alzheimer's disease (AD) has been at the forefront of efforts to address this challenge. Advances in blood-based biomarkers and imaging technologies have enabled researchers to investigate disease years before substantial functional decline occurs. This progress, along with novel disease-modifying therapies, has increased the focus on earlier intervention, biomarker-guided patient recruitment, and prevention-focused trial designs.
Yet as the field gains sophisticated tools for detecting pathology, new questions emerge. What do biomarker findings mean for individual patients? How should they be interpreted alongside clinical symptoms and imaging results? And how should researchers navigate the implications of identifying disease risk before symptoms emerge?
Recent developments surrounding neurofilament light chain (NfL), a structural component of axons released into cerebrospinal fluid and blood following neuroaxonal damage, illustrate both the promise and complexity of this next phase of biomarker-driven neurodegenerative research.
A biomarker expanding beyond a single disease
Over the past several years, AD biomarkers such as p-tau217 have attracted significant attention for their potential to improve screening, patient enrichment, and earlier diagnosis. Their growing use has helped reshape how many trial sponsors design studies and identify participants long before traditional symptoms become pronounced.
But while Alzheimer's-specific biomarkers continue to mature, NfL is generating growing interest across a much broader spectrum of neurological diseases.
Unlike amyloid- or tau-related markers, NfL is not specific to a single disease process. Instead, it is a marker of neuroaxonal injury that can be observed across AD, multiple sclerosis, amyotrophic lateral sclerosis (ALS), Parkinsonian disorders, traumatic brain injury, neuroinflammatory disorders, and other central nervous system (CNS) conditions.
Recent regulatory and diagnostic advances have accelerated industry attention around NfL.
Combined with growing experience using NfL in development programs, including an RNA therapeutic for superoxide dismutase 1 gene-associated ALS, these advances are encouraging sponsors to explore NfL as a potential monitoring tool for disease progression and treatment response across multiple CNS indications and related clinical programs.
Its broad applicability is what makes NfL particularly compelling. Yet as wider adoption increases, it requires careful interpretation as researchers evaluate how factors such as age influence NfL levels and whether age-adjusted reference ranges may be needed for wider implementation.
These discussions reflect the field's increasing focus on ensuring biomarker data is interpreted appropriately across different patient populations. As NfL becomes more widely incorporated into clinical research, standardization and contextualization will be essential for generating reliable and comparable results across sites, studies, and disease indications.
ALS offers a glimpse into NfL's potential
Part of the recent excitement surrounding NfL stems from its growing role in therapeutic development and regulatory decision-making.
One of the most notable examples comes from ALS research. In the development program for a treatment of SOD1-associated ALS, changes in NfL levels became an important component of evidence supporting the therapy's biological activity. Reductions in NfL helped demonstrate that the treatment was affecting underlying disease processes associated with neuroaxonal injury.
The program's subsequent accelerated approval by the US Food and Drug Administration helped raise the profile of NfL across neurodegenerative disease research. More broadly, it provided a high-profile example of how biomarkers may contribute to therapeutic development by complementing traditional clinical assessments and providing additional insight into disease biology.
It is important, however, not to overstate what NfL can do. Unlike disease-specific biomarkers such as p-tau217 in Alzheimer's disease, NfL is not diagnostic for a particular condition. Elevated levels indicate injury but do not reveal the underlying cause. That broad sensitivity is simultaneously one of its greatest strengths and one of the reasons it requires thoughtful interpretation.
Some ALS studies have demonstrated that changes in NfL levels do not always align with corresponding changes in clinical outcomes for neurodegenerative conditions. This may be due to non-disease-modifying mechanisms of the interventions or study limitations that make it difficult to detect statistically significant effects.
The ALS experience reinforces a broader reality: The value of a biomarker lies not just in measuring it accurately but in understanding what it means for individual patients. While advances in laboratory science have improved assay sensitivity, reproducibility, and reliability, giving researchers stronger assurance of their ability to measure biomarkers such as NfL and p-tau217 with precision, the greater challenge increasingly lies in understanding how those findings translate to clinical reality.
How Antibodies Reach Commercial Scale for Diagnostic Tests
This whitepaper follows an antibody's path to full production and shows where a contract partner can take on one step or the whole process.View Whitepaper
A single biomarker result rarely tells the full story. NfL may indicate neuroaxonal injury, but elevated levels alone do not explain why that injury has occurred. Factors such as age, underlying disease, and other clinical findings can all influence interpretation.
This becomes particularly important in neurodegenerative disease, where biomarkers, imaging findings, and clinical symptoms do not always align. Two individuals with similar biomarker profiles may present very differently in clinical practice due to differences in age, cognitive reserve, or overall health status.
As researchers increasingly incorporate biomarkers into clinical trial design, understanding those differences will be key for interpreting study outcomes and selecting appropriate patient populations.
The future value of biomarkers may depend not only on what they reveal individually but on how they are integrated with imaging, clinical assessments, and other patient data to create a more complete picture of disease biology and progression.
Ultimately, this reinforces an important reality for researchers and sponsors alike: The focus is shifting from the value of biomarker measurement to understanding what that context means for patients.
Earlier insights bring a new set of responsibilities
As biomarkers become more sensitive, they are providing earlier insights into disease-related biology, often before individuals experience significant symptoms or receive a formal diagnosis. That capability offers opportunities for earlier intervention while introducing new ethical and operational considerations.
For example, patients with mild cognitive impairment often exist on a continuum between normal aging and eventual diagnosis of AD. Participation in a clinical trial may expose individuals to information about their neurological risk that they did not previously know. In some cases, biomarker findings may suggest underlying pathology before formal clinical diagnosis would otherwise occur.
This raises important questions for sponsors and research teams, such as:
- How should the conversation be structured to communicate the findings, their significance, and broader implications?
- What further evaluation is needed following biomarker testing?
- How should participants be counseled when results indicate elevated risk but uncertainty remains?
- What are the broader implications of generating information that may influence future healthcare decisions, financial planning, or personal decision-making?
These questions become increasingly relevant as neurodegenerative studies move earlier into the disease continuum and rely more heavily on biomarker-guided recruitment strategies. The conversation is opening up to how researchers communicate findings, support participants, and ensure patients understand both the value and limitations of the information being generated.
Essential Tips for Designing and Optimizing qPCR Assays
This guide explores the key considerations for developing robust qPCR assays, covering everything from experimental setup to data interpretation.View How To Guide
As researchers continue pushing detection timelines earlier, ethical readiness may become just as important as scientific readiness. Sponsors that proactively address participant communication, informed decision-making, and long-term support may be better positioned to navigate this evolving landscape.
Clinical trial design must evolve alongside biomarker science
The growth of biomarker-driven research has implications throughout the clinical trial lifecycle.
Historically, many neurodegenerative studies enrolled participants with established diagnoses and measurable symptoms. Earlier-stage development evaluates individuals with mild symptoms, presymptomatic pathology, or biomarker-defined disease risk, which increases complexities regarding informed consent.
Sponsors need communication strategies that help participants understand not only trial procedures but also the potential meaning and limitations of biomarker findings. Recruitment materials, participant education, and long-term engagement plans must account for the emotional and practical implications of learning about future neurological issues.
Also, participants who learn new information about their disease risk or experience changes over the course of a study may require additional support and communication. Building trust and maintaining transparency throughout long-term studies is critical as neurodegenerative research shifts toward earlier intervention.
At the same time, sponsors must continue to ensure that biomarker testing is rigorously validated and appropriately contextualized. As biomarkers take on larger roles in study design and endpoint evaluation, confidence in both assay performance and clinical interpretation is also important.
From discovery to application
The conversation in neurodegenerative research is shifting. While the past decade focused on identifying biomarkers capable of detecting disease earlier, today, there is an increasing spotlight on how those biomarkers can be applied to improve patient selection, study design, and clinical decision-making.
Whether evaluating p-tau217 in Alzheimer's disease, NfL across CNS conditions, or future biomarkers still in development, the opportunity lies in translating scientific advances into evidence that can meaningfully improve patient outcomes.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
